tbuckley/cabot-search huggingface dataset:
AB1035 Management of osteoporosis-related fractures by orthopaedic surgeons: A nation-wide survey
Authors: N. Hammoumraoui, M. El Rakaawi, F. Sadouki, S. Lehtihet, S. Abrouk, H. Djoudi
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Even efficient drugs are now largely available to treat osteoporosis, there is a Lack of treatment by orthopaedists after a low impact fracture in patients with osteoporosis. In a previous fracture incidence study we found that only 3/198 patients with fractures were prescribed a treatment. Orthopaedic surgeons are frequently the only physicians to manage those patients. Very few patients are referred to a rheumatologist or a General practitioner or treated for osteoporosis. Why is this opportunity missed? <h3>Objectives</h3> To evaluate the orthopaedic surgeons’ practices regarding the management of osteoporosis revealed by low impact fractures. <h3>Methods</h3> This is a nationwide study in which 238 orthopaedic surgeons were included. They were interviewed by a unique Interviewer using a standard questionnaire (29 questions). This latter was about 03 main topics: Knowledge, Awareness and Management. <h3>Results</h3> Knowledge about osteoporosis was GOOD in 15% because they Knew either the definition or main Epidemiological data or Clinical aspect or how to diagnose osteoporosis or how to treat osteoporosis. It was MILD in 22% who knew only 3 of the above topics It was INSUFFICIENT in 63% who knew none or only one. Awareness about osteoporosis was GOOD in 12% who Knew the burden or the seriousness or consequences of the fractures. It was MILD in 23% who knew only 1 of the above topics And INSUFFICIENT in 65% who knew none. Management regarding to osteoporosis was GOOD in 8% who do Treat with an efficient drug or refer to a BMD testing or refer to a rheumatologist. It was ABSENT in 92%. <i>Global Evaluation:</i> Only 8% can actually manage efficiently osteoporotic fractures (regarding osteoporosis) <h3>Conclusions</h3> the management of osteoporosis by the orthopaedic surgeons is not sufficient. The probable reasons of that fact are: No course about osteoporosis-related fractures is provided to the orthopaedists during their 4 years of training. No documents are provided to them from the societies acting in the field of osteoporosis. Very few scientific works or conferences are presented in orthopaedic surgery congresses. “Warning” campaigns should be provided to Orthopaedic surgeons. <h3>References</h3> Dreinhofer KE, Anderson M, Feron JM, Herrera A, Hube R,Johnell O, Lidgren L, Miles K, Tarantino U, Simpson H,Wallace WA. Multinational survey of osteoporotic fracturemanagement. Osteoporosis International. 2005 Mar;16 Suppl 2:S44-53. <h3>Disclosure of Interest</h3> None Declared
Abstract 4553: Multiplexed, digital gene expression and fusion transcript analysis to screen for <i>EML4-ALK</i> positive lung cancer
Authors: Maruja E. Lira, Tae-Min Kim, Donghui Huang, Shibing Deng, Youngil Koh, Bogun Jang, Se-Hoon Lee, Doo Hyun Chung, Woo Ho Kim, Dong-Wan Kim, Mao Mao
Journal: Cancer Research (2012)

Abstract Purpose: EML4-ALK fusions occur in approximately 5% of non-small cell lung carcinoma and define a subpopulation of lung cancer patients highly responsive to ALK kinase inhibitors. Current methodologies for detecting presence of ALK rearrangements are labor-intensive, costly, and not ideally suited for screening large number of patient samples. To allow for a sensitive, facile, and inexpensive methodology to detect EML4-ALK fusions, we developed a direct transcript profiling to detect common variants of EML4-ALK fusions. Experimental Design: Using a single multiplex assay, we simultaneously interrogated presence of EML4-ALK transcripts and ALK 3′ over-expression in 8 ALK-positive and 22 ALK-negative NSCLC samples previously tested by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). For controls, we also tested ALK-positive cancer cells lines NCI-H3122 and NCI-H2228, and an ALK-negative cell line A549. Purified RNA from formalin-fixed paraffin-embedded (FFPE) tissue sections was hybridized in duplicates to a biotinylated capture probe and a color-coded reporter probe designed to hybridize to sequences spanning EML4-ALK junction. In addition, multiple probes were created to hybridize within 5′ and 3′ regions of ALK transcript to detect discordant levels between the breakpoint, indicative of fusion event. Purified hybridization complexes are immobilized and aligned on a cartridge where a microscope CCD camera images and counts the molecular color-coded tags attached to reporter probes. The number of reporter counts corresponds to the number of transcripts being interrogated. Results: With this assay, we obtained 100% concordance in EML4-ALK fusion calls to results generated by FISH and IHC analyses. Similar findings were obtained for control cancer cell lines. The assay is highly reproducible and sensitive, detecting ALK-fusion transcripts even in samples with low tumor content. Using the combined strategy of fusion detection and ALK 5′ and 3′ transcript quantification, we were able to validate the status of one patient negative for ALK rearrangement by FISH but positive for ALK protein expression by IHC. Conclusions: We have developed a novel and sensitive methodology to screen for common EML4-ALK fusions in NSCLC. The assay is inexpensive, easy to perform, high-throughput and compatible with FFPE tissue samples. This is a promising technology highly suitable for screening large numbers of tumor samples without the need for cDNA synthesis and PCR amplification. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4553. doi:1538-7445.AM2012-4553
Abstract 1495: Analysis of p53 mutations in human esophageal cancer
Authors: Jonathan M. Jackson, Rosalie K. Elespuru
Journal: Cancer Research (2010)

Abstract Studies on p53 mutations occurring in human tumors have the potential to provide information on causes of human cancer. This is relevant for cancer risk assessment on new products. A database of p53 mutations in human tumors is maintained by Olivier and Hainaut at IARC. We analyzed esophageal squamous cell carcinoma (ESCC), a cancer with known geographic hot spots and life style associations. IARC search allows the rapid determination of sequence distribution, codon location, and strand bias of p53 mutations in tumors stratified by pathology, gender, and lifestyle factors such as tobacco and alcohol use. Although proportions of DNA sequence changes in tumors are provided in IARC profiles, the nature of sequence changes at each base pair is not. Of particular interest are the sequence changes at hot spots. We analyzed the DNA sequence changes among 1032 esophageal mutations occurring at hot spot codons 175, 248, 273, and 282. These are all CpG sites encoding arginine. However, the distribution of mutations was strikingly different at the different sites. At codon 175 (CGC) 98% of the mutations were CAC, virtually all showing strand bias, i.e. G to A from the G containing strand. At codon 248 (CGG), the mutation distribution was 49%TGG and 40% CAG, showing no strand bias, i.e. equally G to A or C to T. At codon 273 (CGT), the mutation distribution was 49% CAT, 33% TGT, and 12% CTT, demonstrating some strand bias but a broader distribution of sequence changes. At codon 282 (CGG), 92% were TGG, again showing striking strand bias. Codons 248 and 282 had identical target sequences but different distributions in the tumors, 282 showing strand bias and 248 showing equivalent distribution of mutations on both strands of DNA. A biased distribution of DNA sequence changes could be related to causal DNA lesions, asymmetric DNA repair, and/or selection of particular mutant phenotypes during tumor progression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1495.
AB0036 Different Regimens of Vitamin D Supplementation Determine an Effect on Phenotype and Function of T Cells in Patients with Systemic Lupus Erythematosus. Results from A Prospective Study: Table 1.
Authors: S. Piantoni, A. Zanola, L. Andreoli, F. Dall'Ara, M. Scarsi, A. Tincani
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> In addition to the classical role on bone metabolism, recent studies highlight that vitamin D (VD) may have an immunomodulatory action on T cells, inhibiting Th-1 and Th-17 response and enhancing Th-2 and T-regulatory (Treg) function. After repeated antigenic presentation, T cells undergo different functional and phenotypical modifications, leading to the differentiation into highly experienced memory T cells (CD45RA+CCR7-) and to the down-modulation of CD28. It may lead to the peripheral expansion of the CD28- T cells, a subpopulation with peculiar effector activities (high g-IFN production) [1]. Systemic Lupus Erythematosus (SLE) is an autoimmune disease in which activation of autoreactive T and B lymphocytes and alteration of Treg functionality may have a pathogenic role [2]. A great prevalence of VD insufficiency has been described in SLE patients (pts), probably due to the low direct sunlight exposition. <h3>Objectives</h3> To study the effect of VD supplementation on the circulating levels of different T-cells subsets and on cytokines production in patients with SLE. <h3>Methods</h3> 51 female SLE pts with a clinically quiescent but serologically active disease were enrolled. 33 pts were supplemented with an intensive regimen (IR) of colecalciferol (300.000UI for the first month and 50.000UI/monthly as maintenance), whereas 18 pts were supplemented with a standard regimen (SR) (25.000UI monthly). Phenotypic analysis of peripheral T lymphocyte and the intracytoplasmatic production of IL-4 and g-IFN from peripheral blood mononuclear cells was evaluated by flow-cytometry. <h3>Results</h3> After 12 months of treatment, a significant increase in the percentage of peripheral induced Treg cells (CD25highCD127lowCCR7-) was observed independently from the regimen of supplementation and a gain of recent thymic emigrants (RTE) Treg cells (CD25highCD127lowCD31+) was detected in pts of IR (table 1). We also observed an increase in the total amount of circulating CD4+CD45RA+CCR7- T cells, whereas a significative reduction of the CD8+CD28- T cells in SLE pts on SR was seen (table 1). In the IR group of patients evaluated for cytokines production (n=8), a reduction of g-IFN/IL-4 (from 12.1 to 3.2; p=0.01) among CD8+ T cells was detected. <h3>Conclusions</h3> VD may have immunomodulatory properties on T cells, enhancing an increase of different subpopulations of Treg cells and promoting the production of Th2 cytokines. <h3>References</h3> Strioga M. Immunology 2011; 134 (1): 17-32; Terrier B et al. Arthritis Res Ther 2012; 14: R221. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4400
Effectiveness of online mindfulness-based interventions in improving mental health: A review and meta-analysis of randomised controlled trials
Authors: M.P.J. Spijkerman, W.T.M. Pots, E.T. Bohlmeijer
Journal: Clinical Psychology Review (2016)

Mindfulness-based interventions (MBIs) are increasingly being delivered through the Internet. Whereas numerous meta-analyses have investigated the effectiveness of face-to-face MBIs in the context of mental health and well-being, thus far a quantitative synthesis of the effectiveness of online MBIs is lacking. The aim of this meta-analysis was to estimate the overall effects of online MBIs on mental health. Fifteen randomised controlled trials were included in this study. A random effects model was used to compute pre-post between-group effect sizes, and the study quality of each of the included trials was rated. Results showed that online MBIs have a small but significant beneficial impact on depression (g = 0.29), anxiety (g = 0.22), well-being (g = 0.23) and mindfulness (g = 0.32). The largest effect was found for stress, with a moderate effect size (g = 0.51). For stress and mindfulness, exploratory subgroup analyses demonstrated significantly higher effect sizes for guided online MBIs than for unguided online MBIs. In addition, meta-regression analysis showed that effect sizes for stress were significantly moderated by the number of intervention sessions. Effect sizes, however, were not significantly related to study quality. The findings indicate that online MBIs have potential to contribute to improving mental health outcomes, particularly stress. Limitations, directions for future research and practical implications are discussed.
A5.13 Serum levels of S100A8/A9 complex and corticosterone correlate to synovial inflammation and cartilage/bone damage in IL-1RA<sup>-/-</sup>MICE, a model system for seronegative arthritis
Authors: E J W Geven, S Abdollahi-Roodsaz, T Vogl, J Roth, D Foell, W B van den Berg, P L E M van Lent
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background and Objectives</h3> In seronegative arthritis high levels of the alarmins S100A8 and S100A9 are measured in serum. These alarmins are released by activated macrophages and can mediate cartilage and bone destruction. Additionally, glucocorticoids have been implicated to stimulate S100A8 and S100A9 synthesis. The aim of this study is to identify serum S100A8/A9 complex as a potential biomarker for joint destruction in seronegative arthritis using IL-1Ra<sup>-/-</sup> mice as an experimental model and whether serum S100A8/A9 levels are associated with serum corticosterone (CORT) levels. <h3>Materials and methods</h3> IL-1Ra<sup>-/-</sup> mice (<i>n</i> = 25, BALB/c background) were macroscopically scored for swelling in the hind paws, at a scale of 0 to 4, at week 15. Serum was collected and levels of IL-1β, IL-4, IL-6, IL-10, IL-17, IFNγ and TNFα were measured by Luminex technology, S100A8/A9 complex levels by ELISA and CORT levels by RIA. Hind paws were isolated and histologically scored for cell influx, cartilage damage (proteoglycan depletion, chondrocyte death, cartilage matrix erosion) and bone erosion, all at a scale of 0 to 8. <h3>Results</h3> Cytokine serum levels were very low (&lt;7 pg/ml), except IL-6 levels (55 ± 32 pg/ml), and no correlation between these levels and macroscopic/microscopic parameters were observed. Serum levels of the S100A8/A9 complex were strongly increased (472 ± 296 ng/ml) compared to WT BALB/c mice (190 ± 55 ng/ml) and correlated significantly with macroscopic score (Pearson r = 0.740, <i>P </i>&lt; 0.0001) and with all microscopic parameters (<i>P</i> &lt; 0.0001, Pearson r &gt; 0.672). When mice were stratified according to serum S100A8/A9 level, the high level group (&gt;500 ng/ml, <i>n</i> = 9) showed a significant increased score for all macroscopic and microscopic parameters when compared to the basal level group (&lt;250 ng/ml, <i>n </i> = 7, <i>P</i> &lt; 0.05) and the medium level group (250-500 ng/ml, <i>n</i> = 9, <i>P</i> &lt; 0.01). Mice with full-blown arthritis (macroscopic score &gt; 2.5) had increased levels of CORT (192 ± 99 ng/ml) compared to non-arthritic mice (392 ± 39 ng/ml, <i>P</i> = 0.007). <h3>Conclusions</h3> Serum levels of S100A8/A9 complex and CORT are strongly correlated with joint swelling, synovial inflammation, cartilage damage and bone erosion in the IL-1Ra<sup>-/-</sup> mice. These findings suggest a role for S100A8/A9 as a potential biomarker for joint destruction in patients with IL1β driven seronegative arthritis and it suggest a role for CORT in the increased S100A8/A9 expression.
Radioiodine Hot Hand Sign
Authors: DAVID SCHECHTER, YOOLPHAT KRAUSZ, S. MOSHE, RIMA RUBINSTEIN, ROLAND CHISIN
Journal: Clinical Nuclear Medicine (1998)

A 32-year-old woman was referred for a whole body I-131 scan 4 weeks after total thyroidectomy for differentiated thyroid carcinoma. Initial scan 72 hours after administration of 5 mCi of I-131 disclosed no abnormal foci. A post-treatment scan performed 10 days after 150 mCi of I-131 showed abnormal uptake throughout the left chest, suggestive of mediastinal and pulmonary metastases, and tracer activity in both hands. Absence of tracer uptake on pre-treatment scan, along with tracer in hands, alerted staff to possible contamination. Repeat imaging of chest after washing revealed no evidence of abnormal tracer uptake. Abnormal uptake on pretreatment scan, even if false positive, may lead to erroneous I-131 administration. It is important to be aware of possible contamination, especially when discordant findings exist, as observed in our patient.
Abstract 271: Rapid regulation of ion channel KCNK5 by ERα in breast cancer cell lines MCF-7 and T47D promotes cell proliferation
Authors: Claudia P. Alvarez-Baron, Philip Jonsson, Stuart Dryer, Cecilia Williams
Journal: Cancer Research (2011)

Abstract Many human breast tumors rely on the proliferative effect of estrogen to propagate. Estrogenic compounds, such as the endogenous ligand 17β-estradiol, signals in various manners, most prominently through the estrogen receptors (ERs). The ERs – alpha and beta, respectively – are transcription factors belonging to the superfamily of nuclear receptors. They act by genomical and non-genomical mechanisms in a ligand-dependent as well as -independent manner, exerting ligand-, promoter- and tissue-specific transcriptional programs. Due to the proliferative effect of ERα in breast it is an important factor in tumor progression. ERα is used clinically as a biomarker and is therapeutically targeted by treatment with antagonistic compounds, for instance tamoxifen. Although extensively studied, the mechanism by which ERα promotes proliferation remains to be fully established. Here we present the finding that ERα rapidly upregulates the potassium ion channel KCNK5 (TASK-2, K2P5.1) in human breast cancer cell lines MCF-7 and T47D. ERα binds at the enhancer of the KCNK5 gene upon estrogen stimulation, subsequently inducing increases in transcript and protein levels of KCNK5. The observed upregulation was strikingly quick, with a sharp peak within one to two hours, before leveling off. Protein levels, however, did not increase until after 12 hours. Treatment with compounds antagonizing ERα transactivation efficiently suppressed this upregulation, further supporting the notion of direct ERα regulation, as compared to non-genomic signaling. Estrogen treatment also increased KCNK5 currents in both cell lines. Various roles for potassium channels in cancer cells have previously been suggested, as for example proliferative, metastatic and anti-apoptotic factors. Knockdown of KCNK5 by siRNA in MCF-7 and T47D cells decreased their proliferation. Additionally, in T47D cells, the estrogen-induced proliferation was repressed when KCNK5 was silenced. This prompts further studies to understand the role of KCNK5 in the proliferation of breast cancer cells and clinical relevance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 271. doi:10.1158/1538-7445.AM2011-271
P642 LOWER RISK OF CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN NON-DIABETIC CHRONIC HEPATITIS B PATIENTS WITH NEW ONSET HYPERLIPIDEMIA: A NATIONWIDE COHORT STUDY
Authors: Y.-W. Huang, T.-C. Wang, C.-K. Hsu, D.-S. Chen, J.-T. Hu, J.-H. Kao, S.-S. Yang
Journal: Journal of Hepatology (2014)
LEFT ATRIAL PERFORMANCE IN THE COURSE OF HYPERTROPHIC CARDIOMYOPATHY: RELATION TO LEFT VENTRICULAR HYPERTROPHY AND FIBROSIS
Authors: Johannes Kowallick, Miguel Silva Vieira, Shelby Kutty, Joachim Lotz, Gerd Hasenfuss, Amedeo Chiribiri, Andreas Schuster
Journal: Journal of the American College of Cardiology (2016)
ESTIMATING EFFECTIVE DOSE OF RADIATION FROM PEDIATRIC CARDIAC COMPUTED TOMOGRAPHY ANGIOGRAPHY USING A 64-SLICE SCANNER: NEW CONVERSION FACTORS RELATING DOSE-LENGTH PRODUCT TO EFFECTIVE DOSE
Authors: Sigal Trattner, Anjali Chelliah, Carrie B. Ruzal-Shapiro, Yanping Xu, Sachin Jambawalikar, Maxwell Amurao, Udo Hoffmann, David J. Brenner, Andrew Jeffrey Einstein
Journal: Journal of the American College of Cardiology (2016)
FRI0094 Relationship between disease duration and response to combination etanercept (ETN)-methotrexate (MTX) therapy in subjects with moderately active rheumatoid arthritis:
Authors: S. Hall, A. Szumski, A. Koenig, T. Jones
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Clinical trial data suggest that the duration of rheumatoid arthritis (RA) may influence response, but most trials have been conducted in patients with severe disease. Less attention has been paid to patients with moderately active RA, who represent a larger group of patients treated in rheumatology clinics. <h3>Objectives</h3> The objective of this post hoc analysis from the PRESERVE trial was to determine the relationship between RA duration and the efficacy of combination ETN–MTX therapy in patients with moderately active RA. <h3>Methods</h3> Enrolled subjects had DAS28 &gt;3.2 and ≤5.1 despite stable oral MTX doses and received open-label ETN 50 mg QW plus MTX for 36 wks. Subjects (n=832) were stratified into disease duration subgroups (≤2 y vs &gt;2 y) and analyzed in a one-way analysis of variance for demographic/baseline (BL) disease variables and for BL/Wk 36 mean weekly MTX doses, and in regression models for Wk 36 annualized radiographic and clinical treatment responses. <h3>Results</h3> Significant differences (<i>P</i>&lt;0.05) between subgroups with disease duration ≤2 y or &gt;2 y were observed for: age (46.5 vs 49.1 y, mean); racial distribution (Asian, 16.8% vs 10.9%); RF+ (62.7% vs 76.7%); and aCCP+ (67.4% vs 81.7%). Disease duration was not significantly associated with mean weekly dosage of MTX at BL or Wk 36. No significant differences were observed between subgroups in the proportions of subjects achieving ACR20/50/70, DAS28 or SDAI low disease activity or remission, normal HAQ (≤0.5), or normal CRP (≤ULN) at Wk 36. Subjects in the &gt;2 y subgroup were significantly more likely to achieve radiographic non-progression (Δ in mTSS ≤0.0; OR 1.76, 95% CI 1.11-2.77), but the estimated mean (SD) BL annual rate of progression was significantly lower in this group (6.0 [6.6] vs 16.6 [39.2], <i>P</i>&lt;0.001). <h3>Conclusions</h3> ETN-MTX therapy was effective in improving RA signs and symptoms in subjects with moderately active RA and an inadequate response to MTX, regardless of disease duration. Subjects with longer disease duration were significantly more likely to achieve non-progression and experienced a lower mean rate of progression. Among subjects with shorter duration, a lower proportion were RF+ and aCCP+; further analyses are planned to examine the distribution of these markers. <h3>Disclosure of Interest</h3> S. Hall: None Declared, A. Szumski Shareholder of: Pfizer Inc., Employee of: Pfizer Inc., A. Koenig Shareholder of: Pfizer Inc., Employee of: Pfizer Inc., T. Jones Shareholder of: Pfizer Inc., Employee of: Pfizer Inc.